Back in 1997, biochemist Bruce Seligmann founded a combinatorial chemistry company called Systems Integration Drug Discovery. And since genomics was hot, he created a subsidiary as well: High Throughput Genomics, to apply the chemistry for high-throughput analysis of genomic samples.

As it turned out, combichem wasn’t that great a business to be in. So last year Seligmann sold the parent company and kept HTG, which alone had a market size “somewhere between $2 billion and $10 billion.”